FDA halts sale of painkiller Palladone

07/14/2005 | Wall Street Journal, The

The FDA said it had not received reports of major problems with the painkiller, which went on the market in February, but data from a Purdue Pharma study suggested that when Palladone was taken with alcohol, it could disable the drug's gradual-release mechanism and cause serious and perhaps fatal reactions. The suspension is a blow to Purdue Pharma, which had counted on Palladone to replace its blockbuster drug OxyContin, which is facing generic competition. A Purdue spokesperson said that, while the FDA action was "unanticipated," the company "complied with their request."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD